Harvard Business Review

OCTOBER 26, 2011

Between 2006 and 2008, more than $1 billion venture-capital dollars were channeled into startups focused on solar, wind and biofuel technologies. Their behavior displays promising parallels to the early days of the biotechnology industry.

Energy 11

Energy Finance IPO Biotechnology 11

Harvard Business Review

MAY 1, 2014

I learned this while leading a turnaround of NPS Pharmaceuticals , a biotechnology company that now specializes in creating treatments for rare diseases. NPS had hit a rough patch in 2006. To save the 20-year-old company, I had to get it operating like a start-up. First, let me give you a little background.

Company 9

Company Pharmaceuticals Biotechnology Short-term 9

Harvard Business Review

DECEMBER 30, 2011

That was the question Todd Pierce asked himself in 2006 after years of experimenting with the full menu of trainings, meetings, and competency models in his capacity as CIO of biotechnology giant Genentech. In other words, what if cultivating a successful inner life was front and center on the leadership agenda?

Development 17

Development Biotechnology CIO Emotional Intelligence 17

Harvard Business Review

FEBRUARY 22, 2013

Cephalon's IPO was in 1991, part of the second wave of biotechnology companies to sell shares to the public. From a failed product to a stock that rose to a value of over $5 billion in much of the 2006-2010 period, Frank Baldino had rebuilt a decimated company, creating meaningful wealth for his shareholders and many of his employees.

Productivity 8

Productivity Products Biotechnology Franchising 8